Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Autor: Marconi V, Ramanan A, de Bono S, Kartman C, Krishnan V, Liao R, Piruzeli M, Goldman J, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams D, Ely E, COV-BARRIER Study Group

Publikováno v: LANCET RESPIRATORY MEDICINE
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

BACKGROUND: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::332f00595ef8b80ae0a2a263cc4b77bb
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16073

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis

Autor: Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, Muram, D, Bradley, J, De Bono, S, Rooney, T, Tanaka, Y, Faraawi, R

Publikováno v: 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20170906-20170909; Stuttgart; DOCRA.28 /20170904/

Background: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA). The objective of this analysis was to evaluate efficacy and safety in pts from RA-BEAM who switched f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a5be0180643c157780129be891144b3
https://doi.org/10.3899/jrheum.170256

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis

Autor: Tanaka, Y, McInnes, IB, Taylor, PC, Byers, NL, Chen, L, de Bono, S, Issa, M, Macias, WL, Rogai, V, Rooney, TP, Schlichting, DE, Zuckerman, SH, Emery, P

Objective Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA). This study was undertaken to analyze changes in lymphocyte cell subsets during baricitinib treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::b262c12c81d6d7ab849b9c7621484576
https://eprints.whiterose.ac.uk/157197/1/Tanaka_et_al-2018-Arthritis_&_Rheumatology.pdf